KUALA LUMPUR: Hap Seng Plantations Holdings Bhd expects crude palm oil (CPO) prices to remain at favourable levels for the remainder of 2026, supported by steady demand from major importer India, Indonesia’s biodiesel mandate, and tight global sunflower oil supplies.
While industry analysts project near-term CPO prices to trade between RM4,400 and RM4,600 per tonne, the planter noted that further upside could be capped by elevated Malaysian palm oil inventories, which are expected to ease toward year-end as seasonal production moderates.
The group added that strengthening El Niño conditions pose a medium-term supply risk heading into 2027, while geopolitical tensions in the Middle East could drive energy, fertiliser, and logistics costs higher.
To safeguard margins, Hap Seng Plantations will focus on improving estate productivity, driving operational efficiencies, and maintaining disciplined cost management.
For the third quarter ended Sept 30, 2026 (3Q26), net profit fell 6.8% year-on-year (y-o-y) to RM48.83 million from RM52.38 million in 3Q25, with basic earnings per share easing to 6.11 sen from 6.55 sen. Profit before tax slipped 7.1% y-o-y to RM61.77 million.
Quarterly revenue declined 4.7% y-o-y to RM161.64 million from RM169.55 million, mainly weighed down by a 14% drop in CPO sales volume to 28,452 tonnes due to delivery timing.
This offset higher CPO and palm kernel (PK) production, up 5% and 9% y-o-y, respectively, as well as stronger average selling prices of RM4,664 per tonne for CPO (versus RM4,320 a year ago) and RM3,670 per tonne for PK (versus RM3,464).
On a quarter-on-quarter (q-o-q) basis, however, net profit surged 24.2% from RM39.32 million in 2Q26, while pre-tax profit climbed 18.6% from RM52.09 million, buoyed by lower unit production costs for CPO.
Sequential revenue fell 19.9% from RM201.73 million as CPO sales volume declined 24% from 37,388 tonnes in the preceding quarter.
For the nine months ended Sept 30, 2026 (9M26), cumulative net profit rose 3.8% y-o-y to RM98.12 million from RM94.52 million, while nine-month revenue increased 10.0% y-o-y to RM555.81 million.
Excluding a one-time prospective fair value loss adjustment of RM28.96 million (RM22.01 million after tax) arising from revised biological asset valuation assumptions effective Jan 1, 2026, nine-month net profit would have been 27% higher y-o-y.
The board did not recommend any interim dividend for the quarter under review.
